论文部分内容阅读
近日,Celgene肿瘤研发管线在欧盟监管方面收获一则喜讯,其抗癌药Revlimid获得欧盟委员会批准扩大适应症,用于复发性和难治性套细胞淋巴瘤。此前Revlimid在欧洲的适应症只有多发性骨髓瘤。(源自:药品资讯网)
Recently, Celgene R & D pipeline has gained good news on EU regulation. Its anti-cancer drug Revlimid has been approved by the European Commission to expand indications for recurrent and refractory mantle cell lymphoma. Previously Revlimid indications in Europe only multiple myeloma. (From: Drug Information Network)